AACR Annual Meeting 2019 Mar 29 - April 3, 2019 Type: Scientific Conference Supporting Materials March 31, 2019 – Abstract 1724 (Oral): Natural history and clinical characteristics of ERBB2 mutant hormone receptor-positive breast cancers: Results from the AACR Project GENIE Registry. March 31, 2019 – Abstract 929 (Oral): Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple ontarget resistance mechanisms: Results from the SUMMIT ‘Basket’ Trial. March 31, 2019 – Abstract 328 (Poster): ADAM17-induced activation of HER receptors mediate resistance to trastuzumab in a subset of moderate HER2-expressing breast cancer cells. March 31, 2019 – Abstract 329 (Poster): Hyperactivation of mTORC1 drives acquired resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers. March 31, 2019 – Abstract 389 (Poster): Role of HER3 signaling pathways in ER+ and HER2+ breast cancers. March 31, 2019 – Abstract 395 (Poster): Aberrant HER2 signaling is a therapeutic target in a subset of castration-resistant prostate cancer. April 1, 2019 – Abstract 1923 (Poster): KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to combination of trametinib (Tm), neratinib (N), and trastuzumab (Tz). April 2, 2019 – Abstract 4459 (Oral): Morphologic and genomic characterization of circulating tumor cells in patients with ERBB2 mutant HER2 non-amplified metastatic breast cancer treated with neratinib. April 2, 2019 – Abstract 4527 (Oral): Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, non-amplified metastatic breast cancer. April 2, 2019 – Abstract 3705 (Poster): Identification of frequent HER2 activating mutations in canine primary pulmonary adenocarcinoma. April 3, 2019 – Abstract 4827 (Poster): The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models. April 3, 2019 – Abstract 4832 (Poster): Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases. Location Atlanta, Georgia
March 31, 2019 – Abstract 1724 (Oral): Natural history and clinical characteristics of ERBB2 mutant hormone receptor-positive breast cancers: Results from the AACR Project GENIE Registry.
March 31, 2019 – Abstract 929 (Oral): Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple ontarget resistance mechanisms: Results from the SUMMIT ‘Basket’ Trial.
March 31, 2019 – Abstract 328 (Poster): ADAM17-induced activation of HER receptors mediate resistance to trastuzumab in a subset of moderate HER2-expressing breast cancer cells.
March 31, 2019 – Abstract 329 (Poster): Hyperactivation of mTORC1 drives acquired resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers.
March 31, 2019 – Abstract 389 (Poster): Role of HER3 signaling pathways in ER+ and HER2+ breast cancers.
March 31, 2019 – Abstract 395 (Poster): Aberrant HER2 signaling is a therapeutic target in a subset of castration-resistant prostate cancer.
April 1, 2019 – Abstract 1923 (Poster): KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to combination of trametinib (Tm), neratinib (N), and trastuzumab (Tz).
April 2, 2019 – Abstract 4459 (Oral): Morphologic and genomic characterization of circulating tumor cells in patients with ERBB2 mutant HER2 non-amplified metastatic breast cancer treated with neratinib.
April 2, 2019 – Abstract 4527 (Oral): Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, non-amplified metastatic breast cancer.
April 2, 2019 – Abstract 3705 (Poster): Identification of frequent HER2 activating mutations in canine primary pulmonary adenocarcinoma.
April 3, 2019 – Abstract 4827 (Poster): The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models.
April 3, 2019 – Abstract 4832 (Poster): Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases.
